U.S. markets open in 1 hour 39 minutes
  • S&P Futures

    4,164.25
    -27.25 (-0.65%)
     
  • Dow Futures

    34,016.00
    -81.00 (-0.24%)
     
  • Nasdaq Futures

    12,696.75
    -150.00 (-1.17%)
     
  • Russell 2000 Futures

    2,003.70
    -4.20 (-0.21%)
     
  • Crude Oil

    75.86
    -0.02 (-0.03%)
     
  • Gold

    1,930.30
    -0.50 (-0.03%)
     
  • Silver

    23.55
    -0.07 (-0.28%)
     
  • EUR/USD

    1.0939
    +0.0027 (+0.25%)
     
  • 10-Yr Bond

    3.3960
    0.0000 (0.00%)
     
  • Vix

    18.36
    +0.49 (+2.74%)
     
  • GBP/USD

    1.2250
    +0.0021 (+0.17%)
     
  • USD/JPY

    128.4310
    -0.1730 (-0.13%)
     
  • BTC-USD

    23,541.86
    -256.61 (-1.08%)
     
  • CMC Crypto 200

    537.66
    -7.66 (-1.40%)
     
  • FTSE 100

    7,844.32
    +24.16 (+0.31%)
     
  • Nikkei 225

    27,509.46
    +107.41 (+0.39%)
     

Further weakness as Concert Pharmaceuticals (NASDAQ:CNCE) drops 13% this week, taking five-year losses to 77%

Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We really hate to see fellow investors lose their hard-earned money. For example, we sympathize with anyone who was caught holding Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) during the five years that saw its share price drop a whopping 77%. The falls have accelerated recently, with the share price down 30% in the last three months. This could be related to the recent financial results - you can catch up on the most recent data by reading our company report.

After losing 13% this past week, it's worth investigating the company's fundamentals to see what we can infer from past performance.

View our latest analysis for Concert Pharmaceuticals

Given that Concert Pharmaceuticals didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

Over five years, Concert Pharmaceuticals grew its revenue at 47% per year. That's well above most other pre-profit companies. So it's not at all clear to us why the share price sunk 12% throughout that time. It could be that the stock was over-hyped before. While there might be an opportunity here, you'd want to take a close look at the balance sheet strength.

The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail).

earnings-and-revenue-growth
earnings-and-revenue-growth

We like that insiders have been buying shares in the last twelve months. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. You can see what analysts are predicting for Concert Pharmaceuticals in this interactive graph of future profit estimates.

A Different Perspective

It's nice to see that Concert Pharmaceuticals shareholders have received a total shareholder return of 21% over the last year. There's no doubt those recent returns are much better than the TSR loss of 12% per year over five years. This makes us a little wary, but the business might have turned around its fortunes. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Even so, be aware that Concert Pharmaceuticals is showing 3 warning signs in our investment analysis , and 1 of those is concerning...

Concert Pharmaceuticals is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here